Skip to main content
. 2018 Jul 24;109(9):2841–2851. doi: 10.1111/cas.13712

Figure 5.

Figure 5

Performance of periostin (POSTN) and carbohydrate antigen 242 (CA242) in diagnosis of CA19.9‐negative pancreatic ductal adenocarcinoma (PDAC) patients. Receiver operating characteristic curves of POSTN, CA242, and POSTN + CA242 in the training, validation, and whole cohorts. To distinguish PDAC CA19.9‐negative from healthy controls (A‐C), and benign disease (D‐F) in the training, validation, and whole cohorts, respectively